Welcome!

Two NIDDK programs, one focused on Type 1 Diabetes (see NIH grant RFA here) and one focused on Obesity (see NIH grant RFA here) funded three different groups with the goal of developing and disseminating targeted mass spectrometry assays for the diagnosis and monitoring of Type 1 Diabetes and Obesity.  While the funding sources are separate, we felt there were obvious synergies in these efforts and formed TaMADOR with the goal of leveraging each other's capabilities and strengths.

Part of the project? Click HERE for internal resources (agendas, meeting logs, etc).  TAMADOR Publications

Type 1 Diabetes Assays

	Quantifying Proteins in Plasma to Democratize Personalized Medicine for Patients with Type 1 Diabetes
	Robust Mass Spectrometric Protein/Peptide Assays for Type 1 Diabetes Clinical Applications

Obesity Assays

	Design and Validation of Easy-to-Adopt Mass Spectrometry Assays of Importance to Obesity
	Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity

• Bethesda 2022
• Seattle 2024

Targeted Mass Spectrometric Assays in Diabetes and Obesity Research

Marriott Bethesda Downtown, MD
December 1, 2022

JOIN US »

Multiplex quantification of protein/peptide hormones and biomarkers involved in obesity and diabetes will facilitate translational scientific research.  Unfortunately, most assays today rely exclusively on antibodies and often there are no widely accepted guidelines or standardized methods to determine the validity of these reagents. Furthermore, many recent publications have highlighted the limitations of many commercial antibodies including failure to detect the intended target. The rigor and reproducibility of many assays commonly used by researchers in the field of diabetes and obesity could be substantially improved applying Mass Spectrometry (MS) instead of relying only on antibodies. Within last decade, major improvements in instrumentation and data handling have made MS–based targeted proteomics a highly reproducible methodology for detecting and quantifying proteins and peptides.

The NIDDK recently funded several projects that aim to use targeted MS approaches for quantifying human plasma/serum proteins and peptides of main interest to the obesity and diabetes research community.

This meeting will focus on advances made by the TArgeted Mass spectrometry Assays for Diabetes and Obesity Research (TAMADOR) pseudo-consortium and possible future directions. This includes insulin, pro-insulin, c-peptide, glucagon, adiponectin, leptin, secretin, and GLP-1, to name a few.

WHEN: December 1, 2022

WHERE: Marriott Bethesda Downtown at Marriott HQ | website »

Tel: +1 301-276-7707

Book your group rate for The Cedars-Sinai Obesity Grant Meeting Room Block

Event Summary:

Start Date: Wednesday, November 30, 2022  3:30PM-6:00PM
Location:  Marriott Grand Ballroom

Thursday, December 1, 2022
Location:  Marriott Grand Ballroom

End Date: Friday, December 2, 2022

Hotel(s) offering your special group rate:
Marriott Bethesda Downtown at Marriott HQ for 199 USD per night
Book your group rate for The Cedars-Sinai Obesity Grant Meeting Room Block

ZOOM OPTION: This meeting will be in-person but the option to participate remotely via Zoom will be provided to all registered participants the day before the meeting.

NOTE: COVID Protocol: CDC, Montgomery County Info Portal, County Policy, and Hotel regulations and guidance will be followed. Masks optional but recommended. Subject to change without notice. 

For logistic questions contact:
Kim Douglas
Kim.douglas@cshs.org
TEL: (310) 654-3947

For scientific content contact:
Dr. Salvatore Sechi
Sechi@nih.gov
TEL: (301)-594-8814 

Pre-Meeting 

November 30, 2022

3:30PM-6:00PM
Location:  Marriott Grand Ballroom

18:30 Dinner in Bethesda (TaMADOR Investigators, NIDDK, Advisory panel members), Location: TBD

December 1, 2022 
Location:  Marriott Grand Ballroom

7:30-8:00 Coffee and Registration

8:00-8:15 Introduction and Logistics by Dr. Salvatore Sechi, NIDDK

8:15-8:25 Welcome and meeting opening by Dr. William Cefalu, Director DEM, NIDDK

8:25-9:10 Keynote Speaker - Mari Demarco, Ph.D., University of British Columbia

Session I: Targeted Mass Spectrometric Assays in Type 1 Diabetes

09:10-09:30 A novel assay to assess the endogenous role of glucagon in glucose homeostasis
Jess Becker, MLS(ASCP), M.S., University of Washington (15’ talks + 5’ Q&A)

09:30-09:50 Using novel antibodies for the measurement of pro-insulin in serum
Michelle Emrick, Ph.D., University of Washington (15’ talks + 5’ Q&A)

9:50-10:10 Coffee Break

10:10-10:40 Keynote Speaker - David A. D'Alessio, MD, Duke University

10:40-11:10 Development and transferability of a combined C-peptide and insulin assay for the study of diabetes.
Andy Hoofnagle, MD/PhD, University of Washington (25’ talks + 5’ Q&A)

11:10-11:30 A vendor neutral platform for sharing interlaboratory data to accelerate diabetes and obesity research.
Mike MacCoss, Ph.D., University of Washington (15’ talks + 5’ Q&A)

11:30-12:50 Lunch Break (on your own)

Session II: Targeted Mass Spectrometric Assays in Obesity Research
12:50-13:20 Keynote Speaker - Rudolph Leibel, MD, Columbia University

13:30-13:50 Health surveillance assay: 60 protein targeted assays for monitoring disease co-morbidities.
Annie Moradian, PhD, Cedars-Sinai Medical Center (15’ talks + 5’ Q&A)

13:50-14:10 Quantitation of proteolyzed peptide hormones involved in the regulation of obesity and diabetes.
Simion Kreimer, PhD, Cedars-Sinai Medical Center (15’ talks + 5’ Q&A)

14:10-14:30 A multiplexed immunoaffinity-MS assay for sensitive detection of adiponectin, leptin, and resistin in obesity samples.
Jie Pu, Ph.D., University at Buffalo

14:30-14:50 Coffee Break

14:50-15:10 A highly multiplexed assay for quantifying a panel of 42 obesity-associated markers in blood plasma/serum.
Tai-Du Lin, Ph.D., Pacific Northwest National Laboratory (15’ talks + 5’ Q&A)

15:10-15:30 Novel methods for the detection of low abundance markers in serum without the need of antibody reagents.
Wei-Jun Qian, Ph.D., Pacific Northwest National Laboratory,
and Jun Qu, Ph.D., University at Buffalo (15’ talks + 5’ Q&A)

15:30-16:30 Discussion on clinical translation of Mass Spectrometry based assays.
Panelists: Jennifer Van Eyk (Cedars-Sinai Medical Center), Kimia Sobhani (Cedars-Sinai Medical Center), Michael MacCoss (University of Washington), Andy Hoofnagle (University of Washington), Weijun Qian (PNNL), Jun Qu (University at Buffalo).
Introduction and moderation by Ravinder Singh (Mayo Clinic)

16:30 Meeting Adjourned

16:30-17:30 Meeting for PIs, NIDDK , and advisors only. (Grand Ballroom)
Advisors: Randie Little, University of Missouri; David Nathan, Harvard
Medical School; Rudolph Leibel, Columbia University; Philipp Sherer, UT
Southwestern (not present at this meeting); James Delany, Advent Health
Research Institute; Ravinder Singh, Mayo Clinic; Robert Fitzgerald, UCSD.

JOIN US »

Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)

Program for the TaMADOR meeting in Seattle, Washington

Location: Brotman Auditorium, University of Washington South Lake Union Campus

Register at: https://diabetesmetabseminars.com/event/targeted-mass-spectrometry-assays-for-diabetes-and-obesity-research-tamador/ 

Publications from U01 DK137097, U01 DK137113, U01 DK124020, and U01 DK124019

1. Wu CC, Tsantilas KA, Park J, Plubell D, Sanders JA, Naicker P, Govender I, Buthelezi S, Stoychev S, Jordaan J, Merrihew G, Huang E, Parker ED, Riffle M, Hoofnagle AN, Noble WS, Poston KL, Montine TJ, MacCoss MJ. Mag-Net: Rapid enrichment of membrane-bound particles enables high coverage quantitative analysis of the plasma proteome. bioRxiv [Preprint]. 2024 Apr 2:2023.06.10.544439. doi: 10.1101/2023.06.10.544439. PMID: 38617345; PMCID: PMC11014469.
2. Karpov OA, Stotland A, Raedschelders K, Chazarin B, Ai L, Murray CI, Van Eyk JE. Proteomics of the heart. Physiol Rev. 2024 Jul 1;104(3):931-982. doi:10.1152/physrev.00026.2023. Epub 2024 Feb 1. PMID: 38300522.
3. Fulcher JM, Swensen AC, Chen YC, Verchere CB, Petyuk VA, Qian WJ. Top-Down Proteomics of Mouse Islets With Beta Cell CPE Deletion Reveals Molecular Details in Prohormone Processing. Endocrinology. 2023 Nov 2;164(12):bqad160. doi: 10.1210/endocr/bqad160. PMID: 37967211; PMCID: PMC10650973.
4. Rasam S, Lin Q, Shen S, Straubinger RM, Qu J. Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome- Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway. J Proteome Res. 2023 Dec 1;22(12):3780-3792. doi: 10.1021/acs.jproteome.3c00463. Epub 2023 Oct 31. PMID: 37906173.
5. Moon S, Alsarkhi L, Lin TT, Inoue R, Tahiri A, Colson C, Cai W, Shirakawa J, Qian WJ, Zhao JY, El Ouaamari A. Transcriptome and secretome profiling of sensory neurons reveals sex differences in pathways relevant to insulin sensing and insulin secretion. FASEB J. 2023 Oct;37(10):e23185. doi:10.1096/fj.202300941R. PMID: 37695721; PMCID: PMC10503313.
6. Nakayasu ES, Bramer LM, Ansong C, Schepmoes AA, Fillmore TL, Gritsenko MA, Clauss TR, Gao Y, Piehowski PD, Stanfill BA, Engel DW, Orton DJ, Moore RJ, Qian WJ, Sechi S, Frohnert BI, Toppari J, Ziegler AG, Lernmark Å, Hagopian W, Akolkar B, Smith RD, Rewers MJ, Webb-Robertson BM, Metz TO; TEDDY Study Group. Plasma protein biomarkers predict the development of persistent autoantibodies and type 1 diabetes 6 months prior to the onset of autoimmunity. Cell Rep Med. 2023 Jul 18;4(7):101093. doi: 10.1016/j.xcrm.2023.101093. Epub 2023 Jun 29. PMID:37390828; PMCID: PMC10394168.
7. Chen YC, Taylor AJ, Fulcher JM, Swensen AC, Dai XQ, Komba M, Wrightson KLC, Fok K, Patterson AE, Klein Geltink RI, MacDonald PE, Qian WJ, Verchere CB. Deletion of Carboxypeptidase E in β-Cells Disrupts Proinsulin Processing but Does Not Lead to Spontaneous Development of Diabetes in Mice. Diabetes. 2023 Sep 1;72(9):1277-1288. doi: 10.2337/db22-0945. PMID: 37364047; PMCID: PMC10450824.
8. Wang X, Niu J, Qian S, Shen S, Straubinger RM, Qu J. Species-Deconvolved Proteomics for In Situ Investigation of Tumor-Stroma Interactions after Treatment of Pancreatic Cancer Patient-Derived Xenografts with Combined Gemcitabine and Paclitaxel. J Proteome Res. 2023 Jul 7;22(7):2436-2449. doi: 10.1021/acs.jproteome.3c00164. Epub 2023 Jun 13. PMID: 37311110; PMCID: PMC10561664.
9. Dakup PP, Feng S, Shi T, Jacobs JM, Wiley HS, Qian WJ. Targeted Quantification of Protein Phosphorylation and Its Contributions towards Mathematical Modeling of Signaling Pathways. Molecules. 2023 Jan 23;28(3):1143. doi: 10.3390/molecules28031143. PMID: 36770810; PMCID: PMC9919559.
10. Kitata RB, Hu LY, Lin TT, Nicora CD, Fillmore TL, Nie S, Hudson RD, Liu T, Leach RJ, Liu AY, Qian WJ, Shi T. Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms. J Proteome Res. 2023 Mar 3;22(3):942-950. doi: 10.1021/acs.jproteome.2c00745. Epub 2023 Jan 10. PMID: 36626706; PMCID: PMC10072162.
11. Martinez TF, Lyons-Abbott S, Bookout AL, De Souza EV, Donaldson C, Vaughan JM, Lau C, Abramov A, Baquero AF, Baquero K, Friedrich D, Huard J, Davis R, Kim B, Koch T, Mercer AJ, Misquith A, Murray SA, Perry S, Pino LK, Sanford C, Simon A, Zhang Y, Zipp G, Bizarro CV, Shokhirev MN, Whittle AJ, Searle BC, MacCoss MJ, Saghatelian A, Barnes CA. Profiling mouse brown and white adipocytes to identify metabolically relevant small ORFs and functional microproteins. Cell Metab. 2023 Jan 3;35(1):166-183.e11. doi: 10.1016/j.cmet.2022.12.004. PMID: 36599300; PMCID:PMC9889109.
12. Pu J, Xue C, Huo S, Shen Q, Qu Y, Yang X, An B, Angel TE, Chen Z, Mehl JT, Tang H, Yang E, Sikorski TW, Qu J. Highly Accurate and Robust Absolute Quantification of Target Proteins in Formalin-Fixed Paraffin-Embedded (FFPE) Tissues by LC-MS. Anal Chem. 2023 Jan 17;95(2):924-934. doi: 10.1021/acs.analchem.2c03473. Epub 2022 Dec 19. PMID: 36534410; PMCID: PMC10581745.
13. Shen S, Wang X, Zhu X, Rasam S, Ma M, Huo S, Qian S, Zhang M, Qu M, Hu C, Jin L, Tian Y, Sethi S, Poulsen D, Wang J, Tu C, Qu J. High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation. Nat Protoc. 2023 Mar;18(3):700-731. doi: 10.1038/s41596-022-00780-w. Epub 2022 Dec 9. PMID: 36494494; PMCID: PMC10673696.
14. Brasil BB, Masaji S, Martins BT, Jiang H, Song N, Athena A S, Lucas B, François M, Wei-Jun Q, Rohit KN, Ronald KC. Apolipoprotein C3 and circulating mediators of preadipocyte proliferation in states of lipodystrophy. Mol Metab. 2022 Oct;64:101572. doi: 10.1016/j.molmet.2022.101572. Epub 2022 Aug 11. PMID: 35964946; PMCID: PMC9418991.
15. Lin TT, Zhang T, Kitata RB, Liu T, Smith RD, Qian WJ, Shi T. Mass spectrometry-based targeted proteomics for analysis of protein mutations. Mass Spectrom Rev. 2023 Mar;42(2):796-821. doi: 10.1002/mas.21741. Epub 2021 Oct 31. PMID: 34719806; PMCID: PMC9054944.
16. Ye Y, Swensen AC, Wang Y, Kaushal M, Salamon D, Knoten A, Nicora CD, Marks L, Gaut JP, Vijayan A, Orton DJ, Mudd PA, Parikh CR, Qian WJ, O'Halloran JA, Piehowski PD, Jain S. A Pilot Study of Urine Proteomics in COVID-19-Associated Acute Kidney Injury. Kidney Int Rep. 2021 Dec;6(12):3064-3069. doi: 10.1016/j.ekir.2021.09.010. Epub 2021 Oct 7. PMID: 34642644; PMCID: PMC8494995.
17. Nakayasu ES, Gritsenko M, Piehowski PD, Gao Y, Orton DJ, Schepmoes AA, Fillmore TL, Frohnert BI, Rewers M, Krischer JP, Ansong C, Suchy-Dicey AM, Evans-Molina C, Qian WJ, Webb-Robertson BM, Metz TO. Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. Nat Protoc. 2021 Aug;16(8):3737-3760. doi:10.1038/s41596-021-00566-6. Epub 2021 Jul 9. PMID: 34244696; PMCID: PMC8830262.
18. Shen S, Li J, Huo S, Ma M, Zhu X, Rasam S, Duan X, Qu M, Titus MA, Qu J. Parallel, High-Quality Proteomic and Targeted Metabolomic Quantification Using Laser Capture Microdissected Tissues. Anal Chem. 2021 Jun 29;93(25):8711-8718. doi: 10.1021/acs.analchem.1c01026. Epub 2021 Jun 10. PMID: 34110778; PMCID: PMC10640922.
19. Wang X, Jin L, Hu C, Shen S, Qian S, Ma M, Zhu X, Li F, Wang J, Tian Y, Qu J. Ultra-High-Resolution IonStar Strategy Enhancing Accuracy and Precision of MS1-Based Proteomics and an Extensive Comparison with State-of-the-Art SWATH-MS in Large-Cohort Quantification. Anal Chem. 2021 Mar 23;93(11):4884-4893. doi: 10.1021/acs.analchem.0c05002. Epub 2021 Mar 9. PMID: 33687211; PMCID: PMC10666926.
20. Sundararaman N, Go J, Robinson AE, Mato JM, Lu SC, Van Eyk JE, Venkatraman V. PINE: An Automation Tool to Extract and Visualize Protein-Centric Functional Networks. J Am Soc Mass Spectrom. 2020 Jul 1;31(7):1410-1421. doi: 10.1021/jasms.0c00032. Epub 2020 Jun 11. PMID: 32463229; PMCID: PMC10362945.
21. Van Eyk JE, Sobhani K. Precision Medicine. Circulation. 2018 Nov 13;138(20):2172-2174. doi: 10.1161/CIRCULATIONAHA.118.036781. PMID: 30571512; PMCID: PMC8260056.
22. Van Eyk JE, Snyder MP. Precision Medicine: Role of Proteomics in Changing Clinical Management and Care. J Proteome Res. 2019 Jan 4;18(1):1-6. doi: 10.1021/acs.jproteome.8b00504. Epub 2018 Oct 22. PMID: 30296097; PMCID: PMC10372929.